• Profile
Close

Long-term clinical outcomes of imiquimod 5% cream vs diclofenac 3% gel for actinic keratosis on the face or scalp: A pooled analysis of two randomized controlled trials

Journal of the European Academy of Dermatology and Venereology Aug 20, 2019

Gollnick H, et al. - Since imiquimod 5% cream (IMIQ) and diclofenac 3% gel (DIC) are commonly used to treat actinic keratosis (AK), however, their long-term impacts after repeated therapy cycles have never been contrasted, researchers conducted this pooled analysis of two randomized controlled trials to compare IMIQ and DIC in AK treatment with the risk of grade III AK or invasive squamous cell carcinoma (SCC) change after 3 years. Immunocompetent adults with 5–10 noticeable AK lesions on the face/scalp and grade I/II AK were eligible for incorporation. A total of 479 patients (IMIQ 242; DIC 237) were included in the full analysis set. The authors concluded that IMIQ has been superior to DIC in clearing AK lesions and preventing histological change to grade III AK or invasive SCC and recurrence over 3 years. Both treatments have been tolerated well.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay